Table 3.
Serum glucose and lipid profile levels distribution among different combinations of HAART taken by study participants at Burayu Health Center, Addis Ababa, Ethiopia, 2012
| Glucose/lipid profile |
NVP versus EFV based combination of ARVs |
P-value | ||
|---|---|---|---|---|
|
NVP (n=65) |
EFV (n=61) |
|||
| N (%) | N (%) | |||
| Glucose |
≤110 |
60(92.3) |
56(91.8) |
0.917 |
| >110 |
5(7.7) |
5(8.2) |
||
| Triglyceride |
<150 |
37(56.9) |
30(49.2) |
0.384 |
| ≥150 |
28(43.1) |
31(50.8) |
||
| Total cholesterol |
<200 |
37(56.9) |
36(59) |
0.812 |
| ≥200 |
28(43.1) |
25(41) |
||
| HDL-cholesterol |
<40 |
28(43.1) |
36(59) |
0.074 |
| ≥40 |
37(56.9) |
25(41) |
||
| LDL-cholesterol |
<130 |
48(73.8) |
49(80.3) |
0.388 |
| ≥130 |
17(26.2) |
12(19.7) |
||
|
Glucose/lipid profile |
D4T versus AZT based combination of ARVs |
P-value |
||
|
D4T (n=47) |
AZT (n=67) |
|||
|
N (%) |
N (%) |
|||
| Glucose |
≤110 |
40(85.1) |
64(95.5) |
0.053 |
| >110 |
7(14.9) |
3(4.5) |
||
| Triglyceride |
<130 |
25(53.2) |
35(52.2) |
0.920 |
| ≥130 |
22(46.8) |
32(47.8) |
||
| Total cholesterol |
<200 |
28(59.6) |
39(58.2) |
0.884 |
| ≥200 |
19(40.4) |
28(41.8) |
||
| HDL-cholesterol |
<40 |
26(55.3) |
33(49.3) |
0.524 |
| ≥40 |
21(44.7) |
34(50.7) |
||
| LDL-cholesterol | <130 |
37(78.7) |
53(79.1) |
0.961 |
| ≥130 | 10(21.3) | 14(20.9) | ||
AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; p, significance level.